<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Haven Shroud on Medium]]></title>
        <description><![CDATA[Stories by Haven Shroud on Medium]]></description>
        <link>https://medium.com/@haven.shroud?source=rss-5dcc029966b2------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*KPgibabaYrXUUxstucrpXg.jpeg</url>
            <title>Stories by Haven Shroud on Medium</title>
            <link>https://medium.com/@haven.shroud?source=rss-5dcc029966b2------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 16:48:45 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@haven.shroud/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[What the Vax?!: Part 4]]></title>
            <link>https://medium.com/@haven.shroud/what-the-vax-part-4-6e4e8a07d55d?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/6e4e8a07d55d</guid>
            <category><![CDATA[comirnaty]]></category>
            <category><![CDATA[disease]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[vaccines]]></category>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Sat, 22 Jan 2022 22:56:37 GMT</pubDate>
            <atom:updated>2022-01-25T13:41:26.391Z</atom:updated>
            <content:encoded><![CDATA[<p>Unforseen circumstances had prevented me from getting this next article published. My apologies! Alas, I am not quite to the halfway point…yet. A lot of the information does get a little bit repetitive but, there’s also some interesting statements by doctors. With that, I’ll dive in!</p><p>3:01:05: FDA Immunogenicity Criteria for Booster Dose •The booster study must be adequately powered to demonstrate that the immune responses induced by the booster dose (serum neutralizing titers against SARS-CoV-2, as measured by seroresponse rates and GMTs), are statistically non-inferior compared to those elicited by the vaccine in the primary series. •The success criteria include demonstration of non-inferiority margins of -10% for seroresponse rates and 1.5 fold for GMTs •Based on consultations with CBER, these criteria are also considered sufficient to support licensure of a booster following full approval of the primary series.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*pQfhEw04MbepnuXGURG13g.jpeg" /></figure><p>3:03:33: Immunogenicity</p><p>3:03:54:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5tFOfoRhtJHFpN4wFObDuQ.jpeg" /></figure><p>3:05:19:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*FgzFR3JRDXqEQXs2sznMVA.jpeg" /></figure><p>3:06:21</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*E-m4HXWayW6ET7TxDB7B-w.jpeg" /></figure><p>3:07:28:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*F8-MjHdPsS_6TQQNyD6-7Q.jpeg" /></figure><p>3:08:01: *Safety</p><p>3:08:07:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*s5M0pGMzSZUH9nfLAlLlAg.jpeg" /></figure><p>3:09:13:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*_qkScGPOSCc3OKoUx9dRSA.jpeg" /></figure><p>3:09:34:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dAyFlDkQgQOOD7jkWsqJtg.jpeg" /></figure><p>I’m not sure why they didn’t use the same number of people. It seems like there isn’t a fair comparison when the number of people used for Dose 2 is 2,682 but, the number of people used for Dose 3 is 289. It doesn’t seem like the comparisons of system events would be very accurate. For instance, the percentage of people who got fevers with Dose 2 was 16.4% and 8.7% with Dose 3. That’s roughly 440 people versus about 23 people. It seems like a rather large discrepancy.</p><p>3:10:22:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jmeODr-6fK5wM6KYS4szQw.jpeg" /></figure><p>Again, the numbers don’t seem fair. Post Dose 2: 12,995 Post Dose 3: 306 With Skin and Subcutaneous Tissue Disorders, both had a 1% reaction. But 1% of 12,995 is about 130 people and 1% of 306 people is about 3. Yet, they are trying to point out that the numbers of adverse events were lower with Dose 3 than Dose 2. Of course the numbers would be lower, if the total number itself is lower; it’s 12,995 versus 306.</p><p>3:11:21:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*r6_GR5huihBb3ER9sX9BXg.jpeg" /></figure><p>Why was it included in the report if it’s unrelated?</p><p>3:14:23: Joohee Lee, M.D./FDA/CBER/Office of Vaccines Research and Review/Division of Vaccines and Related Products Applications 3:14:51:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vkRi-vFia6aq9WLnzYwbUA.jpeg" /></figure><p>Wait, wait, wait, wait, wait! If I’m understanding this correctly, COVID-19 is named for coronavirus disease 2019…but we didn’t know about it until 2020. And it sounds like SARS-CoV-2 was named for coronavirus 2. Was there a 1? Why didn’t we hear about it? This just gets curiouser and curiouse</p><p>3:15:32:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*z0PLx9G-S6mV8m1yUVR3ZQ.jpeg" /></figure><p>3:16:18:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lotiYwkhxuULMjLJZCIhkg.jpeg" /></figure><p>3:40:58: *Summary of Data —— Immunogenicity ~ Immunobridging success criteria for the USA-WA1/2020 strain were met for both pre-specified co-primary immunogenicity endpoints of GMT ratio and difference in seroresponse rates among study participants with no evidence of SARS-CoV-2 infection prior to 1 month after the booster dose. ~ Immunogenicity data to support effectiveness of the booster dose against the Delta variant are limited to exploratory analyses in a small number of participants using non-validated assays. —— Safety ~ Safety data from 306 Phase 2/3 booster recipients do not show evidence of increased reactogenicity relative to Dose 2. ~ Difficult to reach conclusions about relative reactogenicity by age as only 12 participants ages 65-75 years received the booster dose. ~ Lymphadenopathy observed more frequently following the booster dose than after primary series doses (5.2% compared to 0.4%) ~ No deaths, vaccine-related SAEs, or events of myocarditis, pericarditis, anaphylaxis, appendicitis, or Bell’s palsy were reported among the 329 study participants who received the BNT162b2 booster dose.</p><p>3:42:28: BREAK</p><p>And so, I shall end this installment of “What the Vax?!” More is yet to come!</p><p>(Link to the video: https://youtu.be/WFph7-6t34M)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6e4e8a07d55d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Shoulda, Coulda, Woulda….]]></title>
            <link>https://medium.com/@haven.shroud/shoulda-coulda-woulda-8ad9176306e?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/8ad9176306e</guid>
            <category><![CDATA[grammar]]></category>
            <category><![CDATA[critiquing]]></category>
            <category><![CDATA[editing]]></category>
            <category><![CDATA[english]]></category>
            <category><![CDATA[writing]]></category>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Sat, 08 Jan 2022 23:14:38 GMT</pubDate>
            <atom:updated>2022-01-08T23:14:38.454Z</atom:updated>
            <content:encoded><![CDATA[<p>I wasn’t going to write another article until I finished the series I’ve been posting about but, I’ve had a pet peeve for years and it’s time to address it. I was reading a news article the other day and the blunder appeared. The offense happened by a “professional”, nonetheless!</p><p>A few years ago, I had a new writer come to me to critique a story she was working on. I pointed the same error out to her, which happened throughout her story. Even though I tried to be nice about it, it was clear she took offense. Later, on Facebook, she vaguely referred to me as she was describing “someone” whom she asked to help her but, my advice was not helpful because, apparently, she “knows best” and I didn’t know what I was talking about.</p><p>So, what am I talking about? The trifecta of should have, could have, would have. Or they can be spelled with conjunctions; should’ve, could’ve, would’ve. It’s even permissible to relate them as I have done in my title. What IS NOT allowed is should of, could of, would of. Nope. No. Not even a little bit. All it does is make the writer sound unprofessional and immature. So please, just don’t.</p><p>End rant.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8ad9176306e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What the Vax?!: Part 3]]></title>
            <link>https://medium.com/@haven.shroud/what-the-vax-part-3-9a5d7af9e98d?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/9a5d7af9e98d</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[knowledge]]></category>
            <category><![CDATA[comirnaty]]></category>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[education]]></category>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Wed, 29 Dec 2021 15:10:58 GMT</pubDate>
            <atom:updated>2021-12-29T15:10:58.148Z</atom:updated>
            <content:encoded><![CDATA[<p>I’m back! And two days before New Year’s Eve!! In my previous article, “What the Vax?!: Part2b”, I made a challenge to myself, publicly, so I would follow through.</p><p>I just want to remind everyone that I’m not sharing my personal opinion nor trying to change anyone’s mind about the topic. I’m merely sharing the information I learned “straight from the horse’s mouth”, as it were.</p><p>This article picks up where the previous one left off…with Sharon Alroy-Preis &amp; Ron Milo from Israel sharing their findings.</p><ul><li>2:00:52: *Summary: Booster dose in Israel was effective and so far had safety profile similar to the other doses •Booster dose shows ~ 10-fold improved protection against confirmed infection and severe COVID-19 •Post-booster efficacy against Delta similar to pre-waning efficacy against Alpha •Booster dose adverse events not more accute than first or second dose •Based on the above for ages 60+ (and then 50+), the vaccine safety &amp; effectiveness committees in Israel approved booster dose 5 months after 2nd dose for ages 12+ •Administration of booster dose helped Israel dampen severe cases in the 4th wave 2:06:20: “…or every 6 months are you going to have to keep boosting these people?” [The way it was said made me giggle! 😄] 2:06:43: “It’s not clear where this is going.” 2:08:05: “There is some increased risk of myocarditis in younger males.” 2:11:29: “In our vaccinated households, we are starting to see spread into our younger populations who are no longer seemingly protected by herd immunity around them.” [So…does herd immunity work, then? Or doesn’t it?] 2:18:00: Break 2:25:56: *BNT162b2 [COMIRNATY (COVID-19 Vaccine, mRNA)] Booster (Third) Dose 2:27:05: Donna Boyce, MS, Senior Vice President Global Regulatory Affairs Pfizer Inc.</li></ul><p>2:28:01:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*TRnhHvjoehsXu9oOJUh4dQ.jpeg" /></figure><p>2:29:22:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SSZ2FDnuGSNtxbSiFoEAmQ.jpeg" /></figure><p>2:31:08:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*RK0faDIPg3p6ryukz3mPUw.jpeg" /></figure><p>2:32:15: *Benefit-Risk of Booster Dose is Favorable •The demonstrated safety and effectiveness of a third dose of BNT162b2 supported adding a single booster dose to the vaccination schedule •Global RWE demonstrate that the reduction in VE is likely due to waning effectiveness, and Israeli data supports that a booster dose can restore high levels of protection with an acceptable safety profile •Pfizer/BNT is requesting licensure of a single booster dose of BNT162b2 administered intramuscularly at least 6 months after the primary series in individuals &gt; 16 years of age 2:33: William C. Gruber, MD, Senior Vice President Vaccine Clinical Research and Development Pfizer Inc. *Public Health Need *BNT162b2 Vaccine is Highly Protective Against COVID-19 but Duration of Protection Wanes Over Time •Data from the pivotal Phase 3 clinical study (C4591001) showed that 2 doses of BNT162b2 vaccine administered 3 weeks apart confers protection against both symptomatic and severe COVID-19 •Duration of protection of BNT162b2 is currently unknown •Analysis of efficacy up to six months after Dose 2 shows that initial vaccine efficacy slightly wanes over time in the pre-Delta period — 96.2% from 7 days after Dose 2 to &lt; 2 months after Dose 2 — To 90.1% from &gt; 2 months to &lt; 4 months after Dose 2 — To 83.7% for &gt; 4 months up to ~ 6 months after Dose 2 2:35:49: *Waning of immunity has been observed across the world coinciding with penetration of Delta variant •Delta became widespread globally in June and July of 2021 •Reports describing reduced effectiveness of BNT162b2 (and other COVID-19 vaccines) against SARS-CoV-2 infections caused by Delta have surfaced from Israel, the United States, and Qatar [So…are they going to stop using BNT162b2, then….?]•Recently in Israel, reduction in VE has been observed against hospitalization and severe infection after a two-dose BNT162b2 primary series •VE studies to date have not adequately differentiated the impact of Delta from potential waning immunity on recent reductions of vaccine effectiveness •In collaboration with Kaiser Permanente Southern California, Pfizer evaluated overall and variant-specific real-world effectiveness of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospitalizations by time since vaccination</p><p>2:37:46:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*PalU7Klvpd-ZxJ-iPSKknA.jpeg" /></figure><p>2:38:52: *In all age groups, vaccine effectiveness wanes over time against infections but not against hospitalizations 2:41:08: “Effectiveness against severe disease and hospitalizations has begun to decline in Israel.” [Wait! These two statements seem to contradict each other.] 2:41:43: “We may see similar increases in hospitalizations and severe disease in weeks and months for those individuals vaccinated early in the US campaign.” [Why? Because the vaccine wasn’t ready? Because they took it too early? Was it administered wrong??] 2:42:02: •Vaccine effectiveness wanes over time irrespective of the variant concern •Adjusted VE against *SARS-CoV-2 infections*, KPSC members &gt; 12 years of age</p><p>2:43:32:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*L57ivfJQrGDxbnVk2UBAkg.jpeg" /></figure><p>2:46:47: Public Health Need for a Booster: Conclusions •Israel and the United States RWE suggest that VE against COVID-19 infection wanes approximately 6 to 8 months following the second dose when the Delta variant is predominant [But, above it said that it wanes regardless of the variant….]•A retrospective KPSC suggests that VE reductions are primarily due to waning vaccine induced immunity rather than due to Delta escaping vaccine protection •Waning vaccine effectiveness is further supported by the recent FDA requested post-hoc analysis of breakthrough cases in the C4591001 pivotal Phase 3 clinical study •While waning VE against hospitalization was not observed in the US, this should be carefully monitored, as data from Israel suggest that reduced effectiveness against severe disease could eventually follow reductions in VE against SARS-CoV-2 infections 2:47:59: Overview of Clinical Program</p><p>2:48:24:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*K1RAeUEju6CzX7F4jKYkPg.jpeg" /></figure><p>[So…they already knew we’d have all these other variants…? I’m confused 😕]</p><p>2:50:10:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*0LSNAGqdZpjMTv34Rs2pUw.jpeg" /></figure><p>2:51:07:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SwApkgFGjt8OT1PWvpOjAg.jpeg" /></figure><p>2:52:21: Summary of Data for BNT162b2 Booster (3rd Dose) Administered in C4591001: Phase 1 2:52:43: Post-Dose 3 BNT162b2 GMTs Indicate a Substantial Boost and Reduced Gap Between WT and and Beta Neutralization 2:54:47: “Our interpretation…*perhaps* improved protection” 2:56:24: Post-Dose 3 BNT162b2 GMTs Indicate a Substantial Boost to the Delta Variant Similar to Wild Type 2:57:56: Local Reactions by Maximum Severity Within 7 Days of 3rd Dose Similar to Post-Dose 2</p><p>2:58:32:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*tUAXMQqGORexP3Dgs6ox2w.jpeg" /></figure><p>2:58:57: Summary of Data for BNT162b2 Booster (3rd Dose) Administered in C4591001: Phase 3 2:59:33: Basis for Extrapolation of Phase 3 3rd Dose Data to 16-17 and &gt; 55 Year Olds •Immunogenicity — “Studies…may be conducted in a single age group (e g., adults 18-55 years of age), with extrapolation of results to other age groups for which the prototype vaccine has been authorized…” •Safety — 16-17 year olds - based upon post-dose 2 data: *Reactogenicity would be expected to be similar to 18-55 yo — 55 year olds: *Local reactions and systematic events in participants &gt; 55 years after dose 2 were lower than those in younger adults [It seems to be hitting younger people harder]*This predicts lower reactions after the third dose in &gt; 55 yos based on the lower reactogenicity profile seen after the third dose compared to the second dose in 18-55 year olds</p><p>Dr. Gruber isn’t done! But I think I need to leave the rest for my next article…he’s confusing! 😉</p><p>(Link to the video: https://youtu.be/ysV7sY2OMEU)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9a5d7af9e98d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What the Vax?!: Part2b]]></title>
            <link>https://medium.com/@haven.shroud/what-the-vax-part2b-d338f8e7219e?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/d338f8e7219e</guid>
            <category><![CDATA[covid-19-update]]></category>
            <category><![CDATA[information]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[updates]]></category>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Thu, 23 Dec 2021 12:26:02 GMT</pubDate>
            <atom:updated>2021-12-23T12:26:02.624Z</atom:updated>
            <content:encoded><![CDATA[<p>Ok…let’s try this again…. Hopefully the rest of the pictures will upload this time. 🤦‍♀️🤪</p><p>1:14:27:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*xeCYoJamoJGSK201QmyuDw.jpeg" /></figure><p>1:16:32: (A couple of quotes that made me go “hmmmm….”) • “Implausible levels of protection.” • “We don’t expect huge protection against cause of mortality or hospitalization within a week of vaccination and with a first dose only.”</p><p>1:17:24:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*z-7Si6B_5rzoTbR_gUmedA.jpeg" /></figure><p>1:18:41:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XpvLhpQrdQjR3fSEdXX6aA.jpeg" /></figure><p>1:19:33: Characterising Persistently Unvaccinated Individuals — We’re mainly interested in vaccine efficacy some weeks after receipt of the second dose — In highly vaccinated populations, we need to understand the characteristics of the small proportion of people remaining unvaccinated — Did they remain unvaccinated because of recent infection that conferred protection? 1:19:39: The vaccines work brilliantly. But how should we use observational data to guide policy? — It’s very hard to estimate vaccine effectiveness data assembled during the rollout — We need careful and critical evaluations of designs and analysis strategies — Compare estimates from different approaches — Consider effects on negative control outcomes (eg. non-COVID mortality) 1:19:47: Addressing Potential Bias in Studies of COVID-19 Vaccination •Confounding by characteristics predicting both vaccination and outcome — Rollout was in stages, depending on age and whether at particular risk (eg. a healthcare worker) →Conduct analyses stratified by risk groups and accounting for when vaccination became available — Control for a wide range of predictors of vaccination using linked electronic health records →In studies of longer term effects of vaccination, what were the characteristics of the comparison (unvaccinated) group, and what proportion of the unvaccinated were protected because of previous COVID? — Omit those very unlikely to be vaccinated (eg. on end of life care pathway) — Critically appraise “test negative” designs →Check the potential for unmeasured or induced confounding — Be very cautious of apparent short-term benefits of vaccination, because of the potential for unmeasured confounding (eg. by symptoms of COVID) •Deal with the rapidly changing incidence of outcome events — Allow for calendar time, ensuring that all comparisons are among individuals at risk on the same day •Consider the possibility of “cherry picking” — Was there an analysis plan? Was it published before outcome data was available? 1:23:16: “Making incredibly important policy decisions in a short amount of time.”</p><p>Thus concludes Professor Sterne’s presentation.</p><p>1:26:31: Booster Protection Against Confirmed Infections and Severe Disease — Data from Israel, Israeli MOH, Weizmann Institute of Science, Gertner Institute, Hebrew University &amp; Technion 1:28:00: Sharon Alroy-Preis, MD, MPH, MBA/Director of Public Health Services/Ministry of Health (MOH), Israel - Ron Milo, Ph.D/Professor at the Weizmann Institute of Science, Israel - Sharon Alroy-Preis &amp; Ron Milo have no competing financial interests to disclose. Israel MOH and Pfizer have a data sharing agreement. In relation to the immunity waning and booster effectiveness studies presented here, only final results of the analyses were shared with Pfizer. 1:29:20: “…The compliance was not as it was in the previous two weeks.” 1:29:25: The vaccination campaign started early in Israel using the Pfizer BNT 162b2 with three week regimen. 1:29:53: Over 100-fold decrease in cases following vaccination campaign (in conjunction with partially effective lock-down) 1:30:23: “Cases did not go up again.” 1:30:26: Israel reached high levels of population-wide immunity early on (This gets circled back to in a later article, as not completely accurate.)</p><p>1:30:48:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*nbNfcf0GepwnN6FAG7lIgw.jpeg" /></figure><p>1:32:09: During June Alpha was overtaken by the Delta variant in Israel 1:32:33: Israel now experiences its *highest levels of infection*. (Delta variant) *in spite of widespread (&gt;60%) 2nd dose vaccination*. 1:33:04: Daily cases rose by more than 100-fold in 1.5 months •Based on PCR testing performed in Israel for both symptomatic and asymptomatic individuals 1:33:16: Severe Active Cases Increased &gt; 10-fold in a Month •During July - early August: *60% vaccinated with 2 doses*/40% unvaccinated 1:35:10: Waning Immunity was Observed Across Age Groups •Rate of Confirmed SARS-CoV-2 infections stratified by vaccination period and age group •Per 1,000 persons, during July 11, 2021 and July 31, 2021 1:37:30: Waning Immunity Also Observed for Severe Disease in 60+ Group •Per 1,000 persons during July 11, 2021 and July 31, 2021 1:38:42: Waning Immunity Against Severe Disease May Also Occur In Younger Age Groups •Rates of severe COVID-19 stratified by vaccination period and age group per 1,000 persons, July 11 - Aug 15, 2021 1:39:30: Even a seemingly modest 12 percentage point decline in effectiveness could translate to a 5-fold increase in severe cases among the vaccinated •Effectiveness in April for people vaccinated in Jan-Mar was high (eg. 97%) •Effectiveness in July for people vaccinated in January was reduced (eg. 85%)</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*JZQBka9OQX1etL3aks9gGA.jpeg" /></figure><p>1:41:08: Based on evidence for waning in Israel, and the trajectory towards exceeding national hospitalization capacity given the rapid rise in severe cases, Israel decided to begin a 3rd vaccination campaign on July 30th, starting with the elderly. 1:41:40: Booster Campaign Began in Israel on July 30th •&gt;2.8 million booster doses to date — Large majority of elderly population received a 3rd dose — Overall, half of the eligible population received 3rd dose (eligibility begins 5 months after the second dose) 1:42:40: Booster Analysis Covers Most of the 60+ Population •Data on 60+ who were fully vaccinated before March 2021 •Analysis period from August 10 to August 31:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M-Uu2kF2ptUWv7PE4z_TsQ.jpeg" /></figure><p>1:43:00: Reduction in risk due to booster is expected to be observed after ~ 2 week delay 1:45:14: Booster protection against confirmed *infection* as a function of time post vaccination *ages 60+* •Poisson regression adjusted for age, gender, demographic group, 2nd dose period and calendar day •Based on data from August 20 to Sept. 10 1:46:04: Relative risk for booster vaccinated is ~ 11-fold lower against confirmed infections for ages 60+ •Poisson regression adjusted for age, gender, demographic group, 2nd dose period and calendar day •Based on data from August 10 to August 31</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*sdOWDYIm4ehhw4HdA8c9Rg.jpeg" /></figure><p>1:46:41: Similar booster protection against confirmed *infection* is observed *for ages 50-59* •Poisson regression adjusted for age, gender, demographic group, 2nd dose period and calendar day •Based on data from August 13 to Sept. 10 (10-fold protection) 1:47:00: Similar booster protection against confirmed *infection* is observed for *ages 40-49* •Poisson regression adjusted for age, gender, demographic group, 2nd dose period and calendar day •Based on data from August 20 to Sept. 10 (10-fold) 1:47:11: Results were tested by various methods and show high protection •*Using matching* of booster-vaccinated people with corresponding 2-dose vaccinated individuals (similar to Dagan, et al.) →We got *11.6-fold* reduction •*Comparing* 12+ days to 4–6 days post vaccination (when booster has little effect on confirmed infections) →We got *5.4-fold* reduction 1:48:38: Booster provides &gt;10-fold reduction in relative risk of severe disease in 60+ age group •(*Poisson regression* adjusted for age, gender, demographic group, 2nd dose period and calendar day) •Absolute rate difference of 7.5 severe cases per 100K person-days 1:49:02: Vaccine Effectiveness (VE) *against Delta* after *booster dose* returns to VE levels similar to *recent 2nd dose against Alpha* •If VE after waning is 50% for infection and increases 10-fold it becomes 95% •If VE after waning is 80% for severe and increases 10-fold it becomes &gt;97% →Similar to reported values in first few months after 2nd dose (eg. Dagan et al., Polack et al.)</p><p>Hopefully this makes sense to somebody smarter than I…for I…am lost.</p><p>1:50:33: The reproduction number was high in the two months prior to decision on boHopefully this makes sense to somebody smarter than I…for I…am lost.oster dose, with fully vaccinated cases rising rapidly →doubling every 10 days 1:50:57: The reproduction number started decreasing in sync with the expected timing of the booster effect •0.96 = 10 days from infection to confirmation 1:51:31: Large fraction of the older population received a third dose, leading to a substantial decrease in confirmed infection among people over 60y •Booster dose administration to 60+ begins 1:52:06: Following the third dose, severe cases sharply decreased •Booster-dose administration to 60+ begins •Unvaccinated (&lt;20% of adults) •Vaccinated 2+ 3 doses (&gt;80% of adults) 1:52:40: Our model’s projections are that without the booster, or if the booster was administered a few weeks later, hospitalization could have significantly exceeded the national capacity.</p><p>1:55:13:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*ZLlndiQ_m1FpteQxeorugQ.jpeg" /></figure><p>1:56:27:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1Bq-6fOmKgPttvK3jmmmLA.jpeg" /></figure><p>1:56:59: Adverse Events Reported Following 3rd Dose (&gt;2.8 million booster doses administered) under-reporting expected Non-Serious Reports: 1,328 Serious Reports: 19 All hospitalizations and deceased patients were investigated by independent clinical workgroup using all clinical data.</p><p>Oooof!!!! That was *a lot* of information!!!! I’ll leave you to digest it all. Until next time, my nerdy friends…. 🤓</p><p>(Link to the video https://youtu.be/WFph7-6t34M)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d338f8e7219e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What the Vax?!: Part 2a]]></title>
            <link>https://medium.com/@haven.shroud/what-the-vax-part-2a-c2b1d3fe21f9?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/c2b1d3fe21f9</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[covid]]></category>
            <category><![CDATA[data]]></category>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Thu, 23 Dec 2021 12:06:26 GMT</pubDate>
            <atom:updated>2021-12-23T12:06:26.204Z</atom:updated>
            <content:encoded><![CDATA[<p>My apologies for taking so long to get this second part…and addendums… out to you all. I could blame the holidays and make up excuses but, I won’t. I will, however, be real and admit that I probably won’t get Part 3 out until after Christmas but, I’m challenging myself to publish it before New Year’s Eve. There. Now it’s out in the open and I have to follow through. 🙂</p><p>As in my previous two articles, I need to make it known I won’t be stating my opinions regarding either side of the issue nor will I be trying to change anyone’s mind about anything. I simply find the information fascinating and thought I’d pass it along, for what it’s worth. While it’s always best to get information first hand, most people don’t have 8+ hours to sit and watch a meeting about Covid. (Link below)</p><p>Picking up from where my previous article, “What the Vax?!: Part 1&quot; left off, I will delve into the totality of Professor Jonathan Sterne’s presentation.</p><p>1:00:33 “Estimated Facts” brought to you by Isabelle Boutron, Ana-Maria Henao-Restrepo, Nicholas Henschke, Julian Higgins, Fatema Kazi, Philip Krause, Hongchao Pan, Richard Peto, Gemma Villanueva (From what I gather, these are the people that helped the good professor with his research.) 1:00:47 “Real-World” Effectiveness of Vaccines (In his words) randomized *trials* provide the best estimates of effectiveness in the real world but: — A host of urgent questions have not been addressed in randomized trials (general, NOT COVID-specific) He notes that these have almost exclusively been tested *before* Delta. •The ongoing emergency, and amazing success of vaccines, mean that we have to make far reaching policy decisions using observational studies. *Estimated* Effectiveness of vaccines in observational studies *Estimated* Effectiveness of vaccines that is biased, by an unknown amount •Monitoring/Tracking Published Observational Studies on Vaccine Effectiveness 1:02:05: •WHO &amp; Cochrane run a systematic screening/data extraction process on publishing studies •100s of studies are screened per week</p><p>There were charts, graphs, and other visual aids he used to make his points so I attempted crude replications to (hopefully) share the information. 1:02:41:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*a18PeXq5BJJFj0UmZHl-VQ.jpeg" /></figure><p>1:02:59: Monitoring/Tracking Published Observational Studies on Delta Variant — 76 studies on Delta variant asses immunogenicity and/or vaccine effectiveness (number of studies are increasing weekly) •Cohort (n=51) •Test-negative (n=9) •Case Series (n=7) •Case Report (n=4) •Case Control (n=5) Study Populations: — General Community, healthcare workers, elderly, immuno-compromised — Majority of studies assess the mRNA vaccines: •49 studies with mRNA vaccines •34 studies with viral vector vaccines •13 studies with *inactivated* vaccine (Interesting!) 76 Studies of Delta Variant Assess Vaccine — Effectiveness End Points: •Lab-confirmed COVID = 57 •Symptomatic Confirmed COVID = 34 •Severe (definition different from Israel; discussed in later articles)/Hospitalizations = 37 •COVID Death &gt;16</p><p>1:05:36: Methodological Issues in Estimating Vaccine Efficacy During the Rollout *Vaccine Effectiveness in People Aged Over 70 Years (UK) — 667,024 people aged 80+ years; 1,418,760 people aged 70-79 years — Secure Analytics Platform for NHS Electronics Health Records — “My examples are from analyses of UK (English) data but they illustrate general issues in trying to estimate vaccine effectiveness from observational data.” Methodological Issues in Estimating COVID-19 Vaccine Effectiveness •Baseline Confounding (presence of characteristics predicting both vaccine and outcome) 1:06:56:</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*FiaXsu0hzaQed8M4QEegHg.jpeg" /></figure><p>1:10:00: (I found his following statements very enlightening) •UK — “Less deprived people vaccinated than more deprived.” — “Vaccine hesitancy is related to hesitancy.” — “White people got vaccinated faster than people of other ethnicities.” — “People with learning disabilities got vaccinated slower.” 1:10:52: Test Negative Designs, Compare individuals with symptoms who test positive (cases) with those who test negative (controls) •May reduce confounding 1:11:40: “There are consequences to test negative design” — Careful evaluation of the potential for bias in estimates of VE from test negative designs seems warranted 1:12:30: Defining the Comparison Group — Very rapid rollout of vaccination, so unvaccinated people rapidly became vaccinated — Solution: Split follow up time for each individual into unvaccinated and post-vaccinated</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jSxvosmG-zzeQMKdSE2wGg.jpeg" /></figure><p>I had much more all written out but, some of my pictures weren’t loading properly so I’ve decided to publish in smaller bits for this part. So sorry about that!</p><p>(Link to video: https://youtu.be/WFph7-6t34M)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c2b1d3fe21f9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[What the Vax?!: Part 1]]></title>
            <link>https://medium.com/@haven.shroud/what-the-vax-part-1-3c8af4b77162?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/3c8af4b77162</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[wellness]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Sun, 19 Dec 2021 12:47:15 GMT</pubDate>
            <atom:updated>2021-12-19T12:47:15.472Z</atom:updated>
            <content:encoded><![CDATA[<p>Hello fellow health and science nerds! I’m back with the first installment of what I learned about Covid and the various vaccines from watching monthly meetings on YouTube of the FDA and CDC updates.</p><p>I feel it’s necessary to, once again, reinforce the fact that I will not be sharing my opinions nor will I be trying to change anyone’s mind about anything. I simply found the information interesting and potentially useful.</p><p>When I was in school, I hated it and so I’m surprised at myself that now I nerd out about gathering information of any kind. Even science! Which I used to hate in school. Along with math, but that’s another story.</p><p>Without further ado….</p><p>For those interested in finding these gems of information, they are titled “Virtual Meeting: Vaccines and Related Biological Products Advisory Committee”.</p><p>Honestly, the first 15-20 minutes was housekeeping stuff, which I found boring, overall. Although, the introduction of various speakers was a little bit interesting. (It starts at 0:5:18, if you wanna watch. Link below) In that 15-20 minutes, there was also the verifying of credentials and the reading of public records.</p><p>0:20:53: Peter Marks, MD, Ph.D/Director, Center for Biologics Evaluation and Research (CBER), starts off. He seems to believe that there are differing opinions to the interpretation of the data and that there’s a potential need for further dosage of vaccines. He calls them “potentially life saving”. He also refers to the Mrna vaccine, which I found interesting because when it was first introduced, the media initially claimed it had nothing to do with Mrna because of the public’s fears that Mrna would compromise an individual’s DNA. Peter Marks made the claim that 2,000 Americans a day are being infected with COVID.</p><p>0:24:10: Marion F. Gruber, Ph.D/Director, Office of Vaccines Research and Review/CBER/FDA, talked about COMIRNATY. 0:27:22: She shares the Rationale — Data from post-authorization effectiveness studies conducted suggest that the currently U.S. authorized or licensed vaccines remain effective in protecting against severe disease, however, some data suggests that the effectiveness may be waning. (Lots more about waning effectiveness in later articles) 0:28:22: Approval Requirements — Findings of effectiveness of the additional dose is necessary but not sufficient for FDA approval. 0:28:41: Risk/Benefit Considerations — She is quoted as saying, “Evaluation whether the additional dose is ‘safe’ involves weighing whether its benefits outweigh its risks.” 0:29:42: Post-authorization demonstrate increased risk of myocarditis and pericarditis, particularly within 7 days following the second dose of COMIRNATY. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 16 to 17 years of age.</p><p>What I found concerning was that this particular meeting took place in September, yet the above information was only just recently reported on, and not three months ago when it was discovered.</p><p>0:31:22: Ramachandra Naik, Ph.D/Division of Vaccines and Related Products Applications/Office of Vaccines Research and Review/CBER/FDA His intro. was about COMIRNATY, COVID-19 Vaccine, mRNA. 0:32:53: He shared that each 0.3 mL dose contains 30 micrograms of nucleoside — modified messenger RNA (mRNA) encoding the viral spike glycoprotein of SARS-CoV-2. (Nerd alert! I love this kind of stuff)</p><p>0:37:48: Sara Oliver, MD, MSPH, gives summary of VE (Vaccine Efficacy) estimates since introduction of the Delta variant, adults &gt; 18 years of age. 0:46:09: Vaccines remain effective in preventing hospitalizations and severe disease, but might be less effective in preventing infection or milder symptomatic illness. Reasons for lower effectiveness likely include both waning over time and Delta variant.</p><p>Quite honestly, as I listened to her and heard her answer questions, it felt very “copy and pasted”. Like she was borrowing information and repeating what she’d heard, rather than doing any research herself.</p><p>0:59:53: Jonathan Sterne, University of Bristol UK, med school professor — and, yes, he does have an English accent! (Oooh, la la!) He discussed Real-World Effectiveness of COVID-19 Vaccines. Declarations: “I do not have any financial interests with any of the firms/entities that are related to the meeting topic”. “I am co-lead of the Longitude Health and Wellbeing COVID-19 UK National Core Study”. “This study aims to understand the healthy social and economic impacts of the COVID-19 pandemic by uniting established population cohorts and national anonymised electronic health records to inform policy.”</p><p>With that in mind, I will end this article here. Jonathan Sterne had quit a lot to say and present so I’ll pick it up in my next article, “What the Vax?!: Part 2&quot;. If you haven’t read my previous article, introducing this topic, it’s titled “INTRO: What the Vax?!”</p><p>Here’s the link to the meeting, of which I have been referring: <a href="https://youtu.be/WFph7-6t34M">https://youtu.be/WFph7-6t34M</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3c8af4b77162" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[INTRO: What the Vax?!]]></title>
            <link>https://medium.com/@haven.shroud/intro-what-the-vax-dade6cc54d03?source=rss-5dcc029966b2------2</link>
            <guid isPermaLink="false">https://medium.com/p/dade6cc54d03</guid>
            <dc:creator><![CDATA[Haven Shroud]]></dc:creator>
            <pubDate>Sat, 18 Dec 2021 23:44:26 GMT</pubDate>
            <atom:updated>2021-12-18T23:59:16.925Z</atom:updated>
            <content:encoded><![CDATA[<p>Corona. Interesting topic for my first article, no? Don’t worry! I’m not here to try to change anyone’s mind about anything. I’m also not here to give my opinions, ad nauseum. I’m here to share a secret gem I stumbled upon. Ok, it’s not really a secret. You can find it on YouTube. But, did you know there are monthly meetings about data and updates regarding everything Covid related? They’re actually quite fascinating, no matter what your personal opinions are about the topic. The drawback is, each meeting is roughly 8 hours. Luckily for y’all, I have no life! The first meeting I watched in its entirety was from September 17,2021. You might think the information is old but, an interesting thing that comes out of these meetings is that they don’t make their findings public until months later.</p><p>An example is that in this particular meeting, there was discussion about the vax possibly causing myocarditis in older teenage boys, around 16 to 17 years old. However, this information was only recently made public.</p><p>With this in mind, I will be writing a series of follow-up articles about what was discussed in this meeting and sharing information that seems lucrative for us, the public, to know.</p><p>Cheers, Enlightenment, and Knowledge to you all!</p><p>Here’s the link to the meeting: <a href="https://youtu.be/WFph7-6t34M">https://youtu.be/WFph7-6t34M</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=dade6cc54d03" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>